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Abstract
The advent of major histocompatibility complex (MHC) tetramer technology has been a major 
contribution to T cell immunology, because tetramer reagents permit detection of antigen-specific 
T cells at the single-cell level in heterogeneous populations by flow cytometry. However, unlike 
MHC class I tetramers, the utility of MHC class II tetramers has been less frequently reported. 
MHC class II tetramers can be used successfully to enumerate the frequencies of antigen-specific 
CD4 T cells in cells activated in vitro, but their use for ex vivo analyses continues to be a problem, 
due in part to their activation dependency for binding with T cells. To circumvent this problem, 
we recently reported the creation of a new generation of reagents called MHC class II dextramers, 
which were found to be superior to their counterparts. In this review, we discuss the utility of class 
II dextramers vis-a-vis tetramers, with respect to their specificity and sensitivity, including 
potential applications and limitations.
Introduction
Historically, studies related to the detection and functionalities of antigen-specific T cells at 
the single-cell level have been limited because the appropriate reagents and tools were not 
available. Commonly employed readouts included T cell proliferation assays based on 
incorporation of tritiated 3[H]-thymidine or 5-bromo-2'-deoxyuridine (BrdU); 
Carboxyfluorescein succinimidyl ester (CFSE)-labelling; enzyme-linked immunospot 
(ELISPOT) assays; limiting-dilution analysis (LDA); and intracellular cytokine analysis [1–
5]. Although most of these assays are helpful in ascertaining antigen-specific T cell 
responses in mixed cell cultures at the population level, accurate enumeration of the 
frequencies of antigen-specific T cells at the single-cell level has been a major limitation. 
Even assays like ELISPOT or cytokine-analysis can be prone to errors because it is difficult 
to eliminate the contribution of bystander T cells that can be non-antigen-specifically 
activated, leading to the possibility of overestimating the antigen-specific T cells [1]. 
Similarly, although LDA permits analysis of antigen-specific T cells at the single cell-level, 
this assay can never be routinely practical due to both the need to repeatedly activate the 
cells and the laborious nature of the assay [1, 6].
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These circumstances changed, however, with the publication of a 1996 landmark paper by 
Altman et al. describing the creation of major histocompatibility complex (MHC) class I 
tetramer technology; the tetramer reagents were found to be valuable in enumerating the 
frequencies of antigen-specific CD8 T cells by flow cytometry [7]. In 1998, Kappler’s group 
provided a similar platform for CD4 T cells by generating peptide-tethered MHC class II 
tetramers [8]. These discoveries enabled researchers to determine the specificity of antigen-
responsive T cells, particularly with respect to their appearance, disappearance and/or 
persistence in both basic and clinical research investigations (Table 1). MHC tetramers can 
be defined as artificially created soluble fluorochrome-conjugated MHC molecules 
assembled with peptides of interest. Their binding to antigen-specific T cells is captured by 
flow cytometry using the signals emitted by fluorochromes as readouts. However, some 
issues have continued to persist related to the inherent inability of MHC class II tetramers to 
bind CD4 T cells, especially low-affinity T cell receptor (TCR)-bearing autoreactive T cells, 
in spite of the fact that they are antigen-specific [9, 10]. To alleviate this problem, we 
created a newer version of tetramers called MHC class II dextramers for various 
autoantigens and successfully tested their utility in several experimental autoimmune and 
infectious disease models [11–15]. In this review, we discuss the utility of MHC class II 
dextramer reagents, most importantly their advantages over tetramers, as well as potential 
applications and limitations (Table 2). Nonetheless, for extensive details on the derivation 
and use of MHC class II tetramers, readers are encouraged to consult other excellent reviews 
published by various groups [9, 10, 16, 17].
What are MHC class II tetramers and dextramers and how are they created?
To understand the derivation of MHC class II tetramers and dextramers, it is useful to 
understand how MHC molecules display peptides for recognition by T cells. In contrast to 
MHC class I molecules that are composed of a single alpha chain supported by β2-
microglobulin as a scaffolding molecule, MHC class II molecules are made up of two 
chains, α and β. While the peptide-binding groove in the MHC class I molecule is formed by 
the participation of α1 and α2 domains, the α1 and β1 domains from their corresponding 
chains within the MHC class II molecules take part in the formation of grooves to which the 
peptides can anchor. The peptides thus displayed by MHC class I and MHC class II 
molecules are recognized by CD8 or CD4 T cells, respectively, and CD8 and CD4 
molecules act as co-receptors by binding to the corresponding MHC molecules [18]. 
Nonetheless, it should be noted that the affinity of T cell recognition of MHC-displayed 
peptides is weak (KD~ 0.1–500 µM), and engagement of multiple TCRs with as many 
multiple MHC-peptide complexes favors stability of their interactions, leading to enhanced 
avidity [19, 20].
The creation of tetrameric reagents requires expression of soluble MHC molecules that 
represent the extracellular portions in each class of MHC molecule [7, 8]. The presence of a 
single α chain may offer some advantage in allowing MHC class I molecules to be 
expressed more easily than MHC class II molecules in which both α and β chains must stay 
together so peptides can be displayed in the MHC clefts. Several strategies have been 
successfully employed for the expression of MHC class II molecules for various alleles in 
both mice and humans [8, 21–24]. Expression of soluble MHC class II molecules requires 
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the creation of two constructs, one each for α and β chains. A BirA site for biotinylation is 
introduced into one of the two chains, usually the α chain (Fig 1).
To express soluble molecules, various mammalian and non-mammalian expression systems 
have been used [9, 25–27]. However, it is to be noted that creation of MHC constructs 
depends on the intended use of the soluble molecules. Three major approaches are 
commonly used. (1) Derivation of peptide-tethered soluble MHC molecules. In this 
approach, the nucleotide sequence for the desired peptide is covalently tethered to the N-
terminus of the β chain such that the peptide-containing soluble MHC molecules are 
expressed directly [8, 23]. Two advantages have been noted with this approach: (i) the 
peptide-bound MHC molecules are readily available for downstream applications, so the 
loss/instability of peptides is not an issue [8, 27]; and (ii) the covalently assembled peptides 
may provide stability for MHC monomers during protein expression [8, 9]. The major 
disadvantage is the need to generate constructs individually for each peptide of interest. (2) 
Derivation of soluble, empty MHC molecules. Here, α and β chains without peptide 
sequences are expressed to obtain empty molecules, and the desired peptides are then loaded 
exogenously to generate peptide-bound MHC complexes. Technically, this approach is 
versatile and desirable, but the stability of peptides within the groove can be an issue [28–
30]. (3) Derivation of soluble MHC molecules containing class II-associated invariant chain 
peptide (CLIP). This approach is similar to approach 1 as described above, but instead of 
tethering the specific peptide of interest to the N-terminus of the β chain, the CLIP-
conjugated sequence with a site for thrombin cleavage is inserted covalently to the N-
terminus of the β chain. As a result, upon protein expression, the CLIP is cleaved by 
thrombin to obtain empty MHC molecules, into which peptides of interest can be loaded 
exogenously by a peptide-exchange reaction similar to that employed in approach 2 [21, 22, 
31].
In all of these approaches, however, because it is possible for α and β chains to separate 
during expression, it is a common practice to insert leucine-zipper dimerization motifs from 
the transcription factors Fos (3.98 KDa) and Jun (3.92 KDa) to the α and β chains, 
respectively, of MHC class II molecules [23, 32, 33]. By virtue of high-affinity binding 
between Fos and Jun proteins (KD 5.4 × 10−8 M; [34]), the α and β chains are expected to 
stay together as single monomers during protein expression, as well as in the downstream 
steps of protein purification, multimerization and staining by flow cytometry. We commonly 
employ approaches 1 and 3 in our routine tetramer and dextramer preparation.
The purified soluble MHC class II monomers are first biotinylated using biotin ligase (BirA) 
(Fig 1). While the peptide-tethered biotinylated proteins are directly multimerized using 
streptavidin (SA) conjugated with fluorochromes, such as phycoerythrin (PE) or 
allophycocyanin (APC), the CLIP-tethered proteins are first subjected to thrombin cleavage 
to release the CLIP, and the empty molecules are then assembled with peptides in the 
peptide-exchange reaction, followed by multimerization with SA-fluorochromes [21–23]. 
Although the latter approach is versatile in that we can generate reagents for multiple 
antigens by loading the peptides exogenously into empty MHC molecules, we noted a few 
limitations. First, peptides that are readily soluble in water or PBS can be reliably used to 
prepare the reagents, and addition of dimethyl sulfoxide to enhance the solubility of peptides 
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did not yield better results. Second, the sensitivity of tetramers and dextramers generated for 
some peptides was lower than that could be achieved with the reagents generated from the 
use of covalently tethered MHC molecules (unpublished observations).
To prepare multimeric MHC-peptide complexes using SA-fluorochrome conjugates, it is 
important to note that each SA can assemble up to four biotinylated MHC molecules. Hence, 
tetramers typically are expected to possess up to four peptide-bound biotinylated MHC 
molecules. In contrast to tetramers, the dextramers offer an advantage of assembling more 
peptide-bound MHC molecules – up to 20 per dextran molecule [15, 35]. Structurally, 
dextramers contain dextran backbones, which are polymers of glucose molecules attached 
through 1–6 and 1–3 linkages [35]. Each dextran molecule carries multiple moieties of SA 
to which biotinylated peptide-tethered MHC molecules can be assembled [35]. Therefore, 
dextramers can yield MHC-peptide complexes of large molecular weight, allowing them to 
engage multiple TCRs – more than could be achieved with tetramers.
To prepare the dextramers, we use dextran molecules (kind gift from Immudex, Denmark) at 
a working concentration of 3.2 × 10−8 M. Conjugation of dextran molecules with MHC-
peptide molecules depends on the number of SA-fluorochrome-assembled moieties available 
in the dextran backbone. For example, a dextran-PE backbone containing 6.6 SA moieties 
has a molar ratio of 19.8 (6.6 × a valency of 3). Therefore, each mole of dextran-PE can be 
assembled with 19.8 moles of MHC class II monomers. We usually assemble 21 to 22 µg, 
equivalent to 3.17×10−10 moles of MHC class II monomers (~68 KDa) with 1.6 × 10−11 
moles of dextran-PE [15]. On a reaction basis, we routinely use PE-dextramers containing 
6.3 × 10−12 moles, equivalent to 0.45 µg of MHC protein (~3.8 × 1012 molecules), to stain 1 
× 106 cells [15]. Likewise, one mole of dextran-APC with a molar ratio of ~8.7 is used to 
assemble 8.7 moles of MHC class II monomers. To prepare APC-dextramers, we use ~9.5 to 
10 µg of MHC class II protein, equivalent to 1.39 × 10−10 moles, to assemble 1.6 × 10−11 
moles of dextran-APC; and to stain 1 × 106 cells, 2.78 × 10−12 moles (0.2 µg; /~1.67 × 1012 
MHC monomers) are used. Overall, the amount of MHC protein needed to prepare 
dextramer-APC is half the amount needed to prepare dextramer-PE, but the staining 
intensities obtained by the two reagents are comparable [15]. For routine use, the reaction 
conditions for each dextramer reagent are to be optimized. We found that staining at room 
temperature for a minimum of 30 minutes in growth medium (RPMI with 2.5% fetal bovine 
serum and interleukin-2, pH 7.63) was optimum for various MHC class II alleles assembled 
with a wide range of self- and foreign antigens [11, 14, 15].
Are MHC class II dextramers better reagents than MHC class II tetramers?
During the past 10 to 15 years, we have been using MHC class II tetramers in various 
autoimmune disease models in mice, primarily experimental autoimmune encephalomyelitis 
(EAE) induced with myelin proteolipid protein (PLP) 139–151 and myelin oligodendrocyte 
glycoprotein (MOG) 35–55; amoebic encephalitis; experimental autoimmune myocarditis 
(EAM) induced with cardiac myosin heavy chain (Myhc)-α 334–352; and experimental 
autoimmune uveoretinitis induced with interphotoreceptor retinoid-binding protein 201–216 
[11, 15, 23, 33, 36–42]. Although the tetramer reagents were helpful, their use was largely 
limited to enumerating the frequencies of antigen-specific CD4 T cells in cultures activated 
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in vitro, and the direct ex vivo analysis of antigen-sensitized cells was a persistent problem. 
Enrichment procedures involving the use of antibodies to fluorochromes like PE to enrich 
the tetramer-PE-bound CD4 T cells by magnetic separation followed by extrapolating their 
frequencies to the total number of T cells have been commonly employed in the field [16, 
22, 43, 44]. In these settings, the use of enzymes like protein tyrosine kinase inhibitors 
(PKIs) (e.g., Dasatinib, Bristol-Myers Squibb) prior to tetramer staining and enrichment 
procedures appears to enhance the sensitivity of tetramers [45, 46]. These methods can be 
labor intensive, and time consuming. In addition, technically, there also exists a possibility 
of non-antigen-specific cells to be present as contaminants in the enriched populations 
necessitating the use of multiple surface markers to eliminate them [16]. Likewise, 
peripheral blood mononuclear cells (PBMCs) from humans are usually stimulated with 
antigen-pulsed autologous antigen-presenting cells (APCs) for up to ~7 days prior to 
enrichment procedures [47]. Although these analyses may yield valuable information, 
absolute enumeration of the frequencies of antigen-specific T cells can be prone for errors 
leading to inaccurate estimations of their repertoire sizes. In some instances, frequencies of 
antigen-specific T cells can be detected only marginally higher than the background staining 
with the control tetramers because of difficulties in differentiating background staining from 
the specific tetramer staining [48]. To overcome these limitations with tetramers, we made 
efforts to create dextramers utilizing the dextran reagents conjugated with various 
fluorochromes (kind gift from Immudex, Denmark) for IAs/PLP 139–151, IAb/MOG 35–55, 
and IAk/Myhc-α 334–352 [15]. We found that dextramers, but not tetramers, were helpful in 
enumerating the frequencies of antigen-specific CD4 T cells ex vivo in all the above models 
[15]. In addition, we noted that the detection sensitivity of dextramers could be increased by 
at least 4- to 5-fold compared with tetramers. Similarly, the specificity of staining obtained 
with dextramers was better than that could be achieved with tetramers, as background 
staining with the control dextramers was negligible [15]. One other group recently reported 
similar observations by generating the dextramers for human MHC class II allele, HLA-DR1 
[49]. We think that dextramers consisting of multiple MHC-peptide complexes may more 
easily engage with multiple TCRs, leading to enhanced stability of dextramer-T cell 
interactions. As such, the dextramer-bound T cells are less likely to be detached during 
various steps in the staining reactions.
It is a common belief that tetramers bind poorly to low-affinity TCR-bearing T cells, 
because their binding depends on the activation status of T cells, and tetramers therefore are 
unlikely to bind the resting cells even if they are antigen-responsive [33, 50–52]. We and 
others have previously reported that the tetramer+ cells were found almost exclusively 
within the activated (CD4high/CD25+) population [33, 47, 50, 51]. We had proposed that the 
activation status of cells may result in the reorientation or change in the configuration of the 
TCR and cell surface molecules leading to increase in the avidity of TCR-MHC binding 
[33]. To overcome this limitation, we had previously shown that antigen-responsive, rested 
cells can be made to bind with tetramers by first exposing the cells to neuraminidase 
(NASE), which essentially promotes T cell activation by an unknown mechanism [15, 23, 
33]. In addition, removal of sialic acid residues from the surface of T cells by NASE-
treatment may increase TCR affinity as shown with an insulin-insulin receptor system [53]. 
We verified that the dextramers can detect rested cells without the need for NASE-
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treatment, thus overcoming the activation dependency problem noted with tetramers. Based 
on these successes, we expanded the utility of dextramers to detect antigen-specific CD4 T 
cells in target organs, such as brains in EAE mice and hearts in EAM mice, by flow 
cytometry [11, 15]. More importantly, we showed for the first time that MHC class II 
dextramers can be used to detect antigen-specific CD4 T cells in situ directly, both in the 
brain and heart in EAE and EAM models, respectively, by confocal microscopy without 
having to amplify the fluorochrome signals using secondary antibodies, which had been the 
case with MHC class I tetramers [12, 13, 54, 55]. This modality of in situ staining 
considerably reduced the duration of the process to less than a day (~12 hours), as compared 
to up to 3 days with MHC class I tetramers [54, 55]. Furthermore, the amount of reagent 
needed per in situ reaction is 2.5 µg/ml, which is significantly less than required with 
tetramers (20 µg/ml) [15, 56].
By extending the utility of dextramers to phenotype antigen-specific CD4 T cells in relation 
to cytokine-producing cells, we noted the unexpected finding that only a fraction of 
dextramer+ CD4 T cells are capable of producing Th cytokines, while the majority of 
cytokine-producing cells lie within the dextramer− CD4 T cell populations (unpublished 
preliminary observations). Using IAs/PLP 139–151 and IAb/MOG 35–55 dextramers in the 
EAE system and IAk/Myhc-α 334–352 dextramers in the EAM system, we are now 
phenotyping the cytokine-producing dextramer+ and cytokine-producing dextramer− CD4 T 
cells corresponding to Th1, Th2 and Th17 subsets of cytokines to determine whether 
common cytokine signatures exist in different autoimmune diseases. More recently, we 
tested whether dextramers prepared by using naked (fluorochrome-unconjugated) dextran 
backbones (kind gift from Immudex) can be used as APCs to stimulate T cells in bioassays. 
An amount of 0.07 µg was found sufficient to induce robust proliferative responses in T cell 
hybridomas specific to PLP 139–151 and Myhc-α 334–352 (unpublished observations). 
These reagents may be useful in studying T cell-specific responses when the contribution of 
APCs must be avoided. One such potential application is the evaluation of reactive oxygen 
species (ROS) in T cells, whose detection within T cells has been debated, and the argument 
made that the T cells derive ROS as a contaminant from APCs.
Can MHC class II dextramers solve all problems with MHC class II 
tetramers? If not, what improvements can be made?
As described above, we have shown the utility of MHC class II dextramers in several 
experimental systems, finding the dextramers to be superior to their counterparts in terms of 
sensitivity, specificity and applications. If the dextramers can be so much more versatile 
than tetramers, a critical question is whether they can be used as reliable reagents to detect 
CD4 T cells with varied TCR affinity. Unfortunately, the answer is no. We performed an 
experiment to sort the dextramer+ and dextramer− CD4 T cells from PLP 139–151-
sensitized primary T cell cultures by flow cytometry, expecting that the dextramer− cells 
would neither respond to antigen nor bind PLP dextramers upon restimulation. Contrary to 
our expectations, however, the dextramer− cells did respond to PLP 139–151 and also 
stained with PLP dextramers [15]. We sorted CD4 T cells sensitized with PLP 139–151 that 
are negative for PLP 139–151 dextramers, and later stimulated them with PLP 139–151. 
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Approximately, 4% of cells from these cultures were found positive for PLP 139–151 
dextramers, and expectedly, under similar conditions, the PLP 139–151 tetramer− 
counterparts revealed more number of cells (7.2%) to be positive for PLP 139–151 
dextramers [15]. These data suggest that a proportion of antigen-responsive T cells, possibly 
very low-affinity TCR-bearing cells, may not be detected by dextramers. Thus, the need for 
improving the detection sensitivity of dextramers still continues. Reports indicate that pre-
exposure of cells to PKIs enhance the staining intensity of MHC class I tetramers/
dextramers [49, 57]. Mechanistically, PKIs appear to inhibit downregulation of TCRs, 
including CD8 co-receptors, leading to their persistence on the surface of T cells [49, 57]. It 
is possible that similar strategies may work for MHC class II dextramers, although 
participation of CD4 co-receptor is not shown to be critical for binding with MHC class II 
tetramers [8, 58].
In summary, we have analyzed the importance of the utility of MHC class II dextramers, 
especially for detecting autoreactive CD4 T cells in relation to tetramers. While tetramers 
and other similar reagents (pentamers and protein-A conjugated multimers) are being made 
available through several academic (NIH Tetramer Core Facility, Atlanta, GA) and non-
academic sources (Proimmune Inc, Beckman Coulter Inc, and MBL Inc, and TCMetrix Inc), 
dextramers are currently available only commercially (Immudex, Denmark). By creating 
dextramers for various autoantigens, we showed them to be superior to tetramers with 
respect to staining specificity, detection sensitivity, and various applications, but a fraction 
of antigen-specific CD4 T cells may still be undetected by dextramers [11–15, 59]. 
Nonetheless, specifically for ex vivo analysis, the dextramer reagents may offer an 
advantage by enumerating the frequencies of antigen-specific T cells directly, thereby 
avoiding the need to adopt other laborious procedures like enrichment of tetramer-bound T 
cells by magnetic separation [22, 43]. Finally, it should be noted that MHC class II tetramers 
are increasingly being used in clinical research in various areas, including, for example, 
studies of infectious diseases (Lyme arthritis, pulmonary tuberculosis, cytomegalovirus 
infection, and chronic hepatitis), immune-mediated diseases (type I diabetes and multiple 
sclerosis), and allergic diseases (atopic dermatitis and rye grass-associated allergy), and for 
monitoring T cell responses to vaccines (melanoma, influenza, and anthrax) [9, 17, 21, 47, 
60–70]. In all of these evaluations, the frequencies of antigen-specific T cells have been 
reported to range from 0.006% to 3.5% in different body fluids, proving that tetramers are 
helpful in clinical research. But the real challenge is to be able to reliably detect the T cells 
ex vivo in a short period of time without having to stimulate the PBMCs, which is often the 
case with the human samples [21, 63]. Such limitations can possibly be overcome with the 
availability of MHC class II dextramers, since their detection sensitivity is higher than that 
of tetramers [15, 35]. To this end, we are now in the process of creating dextramers for use 
in patients with multiple sclerosis. We believe that potential exists for the use of MHC class 
II dextramers in both basic and clinical research as the reagents become available.
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Figure 1. Derivation of MHC class II dextramers
To produce soluble MHC class II monomers, two constructs, each representing MHC class 
II α and MHC class II β chains, are first created. Generally, we insert the nucleotide 
sequence for specific peptides of interest or thrombin-cleavage site-tagged/CLIP into the N-
terminal end of the β chain construct. Likewise, Fos-and Jun-sequences are attached to the 
C-terminal ends of α and β constructs, respectively, to facilitate stability of α and β chains 
during protein expression, whereas the BirA site for biotinylation is introduced in the α-
construct. The constructs are used to express soluble MHC molecules using Baculovirus in 
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Sf9 insect cells. After biotinylation, the MHC monomers obtained from the constructs 
containing covalently tethered, specific peptide sequences are assembled with dextran 
molecules to obtain dextramers directly. In contrast, the biotinylated proteins generated from 
the CLIP-tethered constructs are first treated with thrombin to release the CLIP peptide, and 
the resulting empty MHC monomers are then used to load peptides of interest exogenously 
by peptide-exchange reaction. For dextramerization, the biotinylated MHC monomers 
generated from any of the above two approaches are mixed with dextran-SA-fluorochrome 
at molar ratios ranging from ~9:1 or 20:1, and the dextramers are then used to stain T cells 
to analyze their frequencies by flow cytometry.
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Table 1
List of MHC class II tetramers and dextramers, and their use for the determination of antigen-specific T cell 
responses in mice and humans




IRBP271–290 and IRBP771–790 Thymic selection of T cells [71]
LCMV GP66–77, GP126–140, GP6–20 and CLIP Detection of LCMV-specific T cells in infected
mice [72]
MOG 35–55, MOG38–49 and hCLIP103–117 Detection of MOG-specific T cells in EAE mice
[40, 73]
OVA323–339, CLIP and LCMV GP61 Detection of OVA-specific T cells in immunized
mice[74]
FliC427–441, 2W1S, OVA323–339 Determination of the frequencies of antigen-
specific T cells in naïve repertoires [43]
HY Detection of antigen-specific T cells in naïve and
immunized mice [75]
IAd
OVA323–339 and influenza HA126–138 Peptide/MHC display and antigen-specificity
studies [8, 76, 77]
IAg7
p8G p6-α62, p8G p11-α72, p8E p6-α62,
p8E p11-α72, insulin, CHGA and HEL
Detection of insulin-specific T cells in NOD mice
[78]
GAD524–543, GAD1040–79, GAD1136–17, p206,
p524, GAD206–220 and GAD471–490
Detection of GAD-specific T cells in NOD mice
[22, 47, 79]
IAk
Myhc-α334–352 and RNase43–56 Detection of Myhc-α-specific T cells in EAM
mice [31]
IRBP201–216, and EHC44–59 Detection of IRBP, and IRBP- and EHC-cross-
reactive T cells in EAU mice [36]
IAs
PLP139–151 and TMEV70–86 Detection of PLP-specific T cells in EAE mice
[33]
PLP139–151 and ACA83–95 Detection of PLP- and ACA-cross-reactive T cells
in EAE mice [14]
IEk
MCC88–103 First report to demonstrate that MHC class II
tetramers detect antigen-specific CD4 T cells [78]
U1–70131–150, U1–70131–150, P(140) and
MCC88–103
TCR-signaling studies, and antigen-specific T cell
responses [58, 80, 81]
Humans
DP4
MAGE-3 Detection of MAGE-3-specific T cells in
vaccinated patients [70]
DQ2
αI- and αII-peptides of gliadin Detection of gliadin-specific T cells in patients
with celiac disease [82]
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MHC class II alleles/epitopes Application
DR*1101
MAGE-A3191–205, MAGE-A3281–295 and Epitope-binding studies [83]
MAGE-A3286–300
DR0301
IGRP peptides and Flu MP169–181 Tetramer-guided epitope mapping [84]
DR0401
IGRP peptides and Flu HA306–318 Tetramer-guided epitope mapping [84]
DRB1
Bet v 1141–155, Der p 1 16–30, Der p 1 171–185
and
T cell responses in allergy [85]
Phl p 1 194–208
DRB1*0101
HIV Gag p24294–313, Gag p24264–283, TT830–843,
influenza HA307–319 and CMV pp65108–127
Detection of HIV-, tetanus toxoid-, influenza-, or
CMV-specific T cells by magnetic bead
enrichment [86]
HA307–319 and HA306–318 Detection of influenza-specific T cells [87, 88]
Fel d 1 Detection of Fel d 1-specific T cells in atopic
dermatitis patients [64]
DRB1*0401
HA306–318 and GAD Detection of influenza-specific T cells in vaccine-
recipients [88]
MOG97–109 Detection of MOG-specific T cells [89]
OspA164–175 Detection of OspA-specific T cells in lyme
arthritis patients [62]
Human CII, HCgp39 and Osp-A Detection of cartilage antigen-specific T cells in
rheumatoid arthritis patients [90]
HCV 1248, HCV 1579 and HCV 1770 Detection of HCV-specific T cells in viral
hepatitis [21, 63]
MART 151–173 Detection of MART-1-specific T cells in vaccine-
recipients [69]
Lol P1 Detection of allergen-specific T cells in allergic
individuals [65]
DRB1*0402
Dsg3 Detection of Dsg3-specific T cells in pemphigus
vulgaris [91]
DRB1*0404
PA112–127 Detection of antigen-specific T cells in recipients
of Anthrax vaccine [67]
HIV Gag p24164–183 and HCV NS31248–1261 Detection of HIV- or HCV-specific T cells by
magnetic bead enrichment [86]
DRB1*1302
PA373–393 and PA381–392 Detection of antigen-specific T cells in recipients
of Anthrax vaccine [67]
DR3
MTB 1–13 and CMV pp65510–522 Detection of MTB- and CMV-specific T cells in
patients/vaccine-recipients [92]
DR4
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MHC class II alleles/epitopes Application
HA p306–318 and NY-ESO-1 p119–130 Detection of influenza- or NY-ESO-1-specific T
cells by immunoscope [25]
Ag85B and ESAT-6 Detection of MTB-specific T cells in patients with
pulmonary tuberculosis [61]
DR401
GAD65555–567 and HSV-p61 Detection of GAD-specific T cells in type 1
diabetes [47]
DR404





MOG 35–55 Detection of MOG-specific T cells in EAE mice
[59]
IAk
Myhc-α 334–352 and RNase 43–56 Detection of Myhc-α-specific T cells in EAM
mice and CVB3-infected mice [11, 15]
IAs
PLP139–151 and TMEV70–86 Detection of PLP-specific T cells ex vivo, in vitro
and in situ in EAE mice [12, 13, 15]
PLP139–151 and ACA83–95 Detection of PLP- and ACA-cross-reactive T cells
in ACA infected mice [14]
Humans
HLA-DR1
Influenza A HA307–319 and HIV-1 p24
Gag299–312
Detection of influenza-specific T cells [49]
HLA-DP2
Mim2, Mim2 and Be, and PLXNA4 and Be Detection of Be-specific T cells [93, 94]
*
This list is intended to capture broad applications of tetramer and dextramer reagents in basic and clinical research, and by no means is a 
comprehensive list. As such, some reagents may not have been listed, and the authors wish to acknowledge this limitation.
IRBP, interphotoreceptor retinoid-binding protein; LCMV, Lymphocytic choriomeningitis virus; GP, glycoprotein; CLIP, Class II-associated 
invariant chain peptide; MOG, myelin oligodendrocyte glycoprotein; EAE, experimental autoimmune encephalomyelitis; OVA, ovalbumin; HA, 
hemagglutinin; FLiC, flagellar filament structural protein; HY, Y chromosome-encoded transplantation antigens; NOD, non-obese diabetic; GAD, 
glutamic acid decarboxylase; CHGA, chromogranin A; HEL, hen egg lysozyme; Myhc-α, cardiac myosin heavy chain-α; RNase, Ribonuclease; 
EAM, experimental autoimmune myocarditis; EHC, Ehrlichia canis; EAU, experimental autoimmune uveitis; PLP, myelin proteolipid protein; 
TMEV, Theiler’s murine encephalomyelitis virus; ACA, Acanthamoeba castellanii; MCC, moth cytochrome C; MAGE, melanoma-associated 
antigen; IRGP, islet-specific glucose-6-phosphatase catalytic subunit-related protein; MP, Matrix protein; Bet v 1, Betula verrucosa; Der p 1, 
Dermatophagoides pteronyssinus; Phl p 1, pollen allergen; HIV, Human immunodeficiency virus; Gag, group-specific antigen; TT, Tetanus toxoid; 
CMV, Cytomegalovirus; OspA, Borrelia burgdorferi outer surface protein-A; CII, type 2 collagen; HCV, Hepatitis C virus; MART, from Melan-
Ae/melanoma antigen recognized by T cells; Lol P1, rye grass allergen; HCgp, Human cartilage glycoprotein; Dsg3, desmoglein3; PA, protective 
antigen of Bacillus anthracis; NS, nonstructural protein; MTB, Mycobacterium tuberculosis; NY-ESO-1, New York esophageal squamous cell 
carcinoma; Ag85B, Antigen 85; ESAT-6, Early Secretory Antigenic Target; CVB3, coxsackie virus B3; Mim2, mimotope-2; Be, beryllium
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Table 2
Advantages of using MHC class II dextramers over tetramers for detecting antigen-specific, autoreactive CD4 
T cells.
Parameters Tetramers Dextramers
a. Generation of reagents
    • Creation of MHC constructs,
      expression of
      soluble MHC monomers and
      biotinylation
Steps are similar for both the reagents






b. Staining characteristics based on flow cytometry
    • Number of MHC monomers per
      reaction
12.6 × 10−12 moles 2.78 × 10−12 moles
    • Specificity Yes Yes, but enhanced
    • Sensitivity Low High
    • Duration Variable (usually 2 to 3
hours in our hands)
Relatively short (0.5 to 2 hours)
c. Applications
    • Detection of T cells ex vivo May or may not work Reliable and consistent
    • Detection of T cells activated in
      vitro
Useful Useful
    • Detection of T cells in situ May work Reliable and consistent
    • Cytokine-phenotyping by flow
      cytometry
Yes Yes, but with enhanced sensitivity
    • Bioassay Yes Yes
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